Severe adverse drug reactions to biological disease-modifying anti-rheumatic drugs in elderly patients with rheumatoid arthritis in clinical practice

Clinical and Experimental Rheumatology

Volumn 36, Issue 1, 2018, Pages 29-35

  Leon, Leticia ^a,b   Gomez, Alejandro ^a   Vadillo, Cristina ^a   Pato, Esperanza ^a   Rodríguez Rodríguez, Luis ^a   Jover, Juan ángel ^a,c   Abásolo, Lydia ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b CAMILO JOSÉ CELA UNIVERSITY   (Spain)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

BDMARDs; Diverse drug reactions; Elderly; Rheumatoid arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; BIOLOGICAL PRODUCT; CERTOLIZUMAB; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; NONSTEROID ANTIINFLAMMATORY AGENT; RITUXIMAB; TOCILIZUMAB; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT;

ADVERSE DRUG REACTION; AGED; ARTICLE; CLINICAL PRACTICE; CONGESTIVE HEART FAILURE; DEMOGRAPHY; DISEASE SEVERITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HERPES ZOSTER; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; LONGITUDINAL STUDY; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASM; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OUTPATIENT DEPARTMENT; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SURVIVAL TIME; TUBERCULOSIS; AGE; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; KAPLAN MEIER METHOD; MULTIVARIATE ANALYSIS; OPPORTUNISTIC INFECTION; PROPORTIONAL HAZARDS MODEL; SEVERITY OF ILLNESS INDEX; SPAIN; TREATMENT OUTCOME;

AGE FACTORS; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; INCIDENCE; KAPLAN-MEIER ESTIMATE; LONGITUDINAL STUDIES; MALE; MULTIVARIATE ANALYSIS; OPPORTUNISTIC INFECTIONS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SPAIN; TREATMENT OUTCOME;

EID: 85042146412     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. RASCH EK, HIRSCH R, PAULOSE-RAM R, HOCHBERG MC: Prevalence of rheumatoid arthritis in persons 60 years of age and older in the United States: effect of different methods of case classification. Arthritis Rheum 2003; 48: 917-26
2. KIEVIT W, FRANSEN J, de WAAL MALEFIJT MC, den BROEDER AA, van RIEL PL: Treatment changes and improved outcomes in RA: an overview of a large inception cohort from 1989 to 2009. Rheumatology (Oxford) 2013; 52: 1500-8
3. SINGH JA, WELLS GA, CHRISTENSEN R et al.: Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011: CD008794
4. LAMPROPOULOS CE, ORFANOS P, BOURNIA VK et al.: Adverse events and infections in patients with rheumatoid arthritis treated with conventional drugs or biologic agents: a real world study. Clin Exp Rheumatol 2015; 33: 216-24
5. NANAU RM, NEUMAN MG: Safety of antitumor necrosis factor therapies in arthritis patients. J Pharm Pharm Sci 2014; 17: 32-61
6. SINGH JA, CAMERON C, NOORBALOOCHI S et al.: Risk of serious infection in biological treatment of patients with rheumatoid arthri-tis: a systematic review and meta-analysis. Lancet 2015; 386: 258-65
7. WHO: Draft Guidelines for Adverse Event Reporting and Learning Systems. WHO Document Production Services, Geneva, Switzerland 2005
8. MedDRA. Meddra maintenance and support services organization http://www.Meddramsso. ORG/
9. ZINK A, STRANGFELD A, SCHNEIDER M et al.: Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials. Arthritis Rheum 2006; 54: 3399-407
10. ROCHON PA, FORTIN PR, DEAR KB, MINAKER KL, CHALMERS TC: Reporting of age data in clinical trials of arthritis. Deficiencies and solutions. Arch Intern Med 1993; 153: 243-8
11. FILIPPINI M, BAZZANI C, FAVALLI EG et al.: Efficacy and safety of anti-tumour necrosis factor in elderly patients with rheumatoid arthritis: an observational study. Clin Rev Allergy Immunol 2010; 38: 90-6
12. CHEVILLOTTE-MAILLARD H, ORNETTI P, MISTRIH R et al.: Survival and safety of treatment with infliximab in the elderly population. Rheumatology (Oxford) 2005; 44: 695-6
13. GENEVAY S, FINCKH A, CIUREA A, CHAMOT AM, KYBURZ D, GABAY C: Tolerance and effectiveness of anti-tumor necrosis factor alpha therapies in elderly patients with rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2007; 57: 679-85
14. MIGLIORE A, BIZZI E, LAGANA B et al.: The safety of anti-TNF agents in the elderly. Int J Immunopathol Pharmacol 2009; 22: 415-26
15. SCHNEEWEISS S, SETOGUCHI S, WEINBLATT ME et al.: Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum 2007; 56: 1754-64
16. DORAN MF, CROWSON CS, POND GR, O'FALLON WM, GABRIEL SE: Predictors of infection in rheumatoid arthritis. Arthritis Rheum 2002; 46: 2294-300
17. CROWSON CS, HOGANSON DD, FITZGIBBON PD, MATTESON EL: Development and validation of a risk score for serious infection in patients with rheumatoid arthritis. Arthritis Rheum 2012; 64: 2847-55
18. STRANGFELD A, EVESLAGE M, SCHNEIDER M et al.: Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis 2011; 70: 1914-20
19. THORNE C, BENSEN WG, CHOQUETTE D et al.: Effectiveness and safety of infliximab in rheumatoid arthritis: analysis from a Canadian multicenter prospective observational registry. Arthritis Care Res (Hoboken) 2014; 66: 1142-51
20. BURMESTER GR, MATUCCI-CERINIC M, MARIETTE X et al.: Safety and effectiveness of adalimumab in patients with rheumatoid arthritis over 5 years of therapy in a phase 3b and subsequent postmarketing observational study. Arthritis Res Ther 2014; 16: R24
21. WIDDIFIELD J, BERNATSKY S, PATERSON JM et al.: Serious infections in a populationbased cohort of 86,039 seniors with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2013; 65 :353-61
22. ABASOLO L, LEON L, RODRIGUEZ-RODRIGUEZ L et al.: Safety of disease-modifying antirheumatic drugs and biologic agents for rheumatoid arthritis patients in real-life conditions. Semin Arthritis Rheum 2015; 44: 506-13
23. McKEE M, BRITTON A, BLACK N, McPHERSON K, SANDERSON C, BAIN C: Methods in health services research. Interpreting the evidence: choosing between randomised and non-randomised studies. BMJ 1999; 319: 312-15
24. FAVALLI EG, BUGATTI S, BIGGIOGGERO M, CAPORALI R: Treatment comparison in rheumatoid arthritis: head-to-head trials and innovative study designs. BioMed Research International 2014; Article ID 831603, 17 pages. Available at: http://dx.doi. org/10.1155/2014/831603
25. SUGIHARA T, HARIGAI M: Targeting low disease activity in elderly-onset rheumatoid arthritis: current and future roles of biological disease-modifying antirheumatic drugs. Drugs Aging 2016; 33: 97-107
26. van DARTEL SA, FRANSEN J, KIEVIT W et al.: Predictors for the 5-year risk of serious infections in patients with rheumatoid arthritis treated with anti-tumour necrosis factor therapy: a cohort study in the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Rheumatology (Oxford) 2013; 52: 1052-57
27. DIXON WG, ABRAHAMOWICZ M, BEAUCHAMP ME et al.: Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis. Ann Rheum Dis 2012; 71: 1128-33
28. EMERY P, GALLO G, BOYD H et al.: Association between disease activity and risk of serious infections in subjects with rheumatoid arthritis treated with etanercept or disease-modifying anti-rheumatic drugs. Clin Exp Rheumatol 2014; 32: 653-60
29. GOODSON N: Coronary artery disease and rheumatoid arthritis. Curr Opin Rheumatol 2002; 14: 115-20
30. MARADIT-KREMERS H, CROWSON CS, NICOLA PJ et al.: Increased unrecognized coronary heart disease in rheumatoid arthritis: a population-based cohort study (abstract). Arthritis Rheum 2004; 50 (Suppl.): S688
31. GABRIEL SE, CROWSON CS, O'FALLON WM: Comorbidity in arthritis. J Rheumatol 1999; 26: 2475-9
32. AVINA-ZUBIETA J.A., THOMAS J, SADATSAFAVI M, LEHMAN A.J, LACAILLE D: Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis 2012; 71: 1524-29
33. MUROTA A, KANEKO Y, YAMAOKA K, TAKEUCHI T: Safety of biologic agents in elderly patients with rheumatoid arthritis. J Rheumatol 2016; 43: 1984-8
34. GRIJALVA CG, CHEN L, DELZELL E et al.: Initiation of tumor necrosis factor-antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA 2011; 306: 2331-9
35. LACAILLE D, GUH DP, ABRAHAMOWICZ M, ANIS AH, ESDAILE JM: Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis. Arthritis Rheum 2008; 59: 1074-81
36. CURTIS JR, PATKAR N, XIE A et al.: Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor antagonists. Arthritis Rheum 2007; 56: 1125-33